Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of Albumin-bound Formulation of Docetaxel for Intravenous Infusion in Patients With Advanced Solid Tumors: A Phase 1, Single-center, Open-label, Dose-escalation Study
Latest Information Update: 04 Jan 2024
At a glance
- Drugs Docetaxel (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors CSPC ZhongQi Pharmaceutical Technology
Most Recent Events
- 27 Jan 2022 Planned End Date changed from 15 Jul 2023 to 15 Dec 2023.
- 27 Jan 2022 Planned primary completion date changed from 15 Mar 2022 to 15 Dec 2022.
- 31 Dec 2020 Status changed from not yet recruiting to recruiting.